Middle-income countries have gained greater access to a variety of needed cardiovascular medicines, but remain unable to close the gap with wealthy nations, according to a recent analysis of sales data in dozens of countries.
From 2008 to 2018, the compound annual growth rate for all cardiovascular medicines was nearly 10% in middle-income countries compared with almost 1% in high-income nations. As a result, use of those drugs was six times higher in wealthy countries than lower-income nations in 2018, compared to a 15-fold difference a decade earlier.
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
.jpg?itok=F5fb_yNp)
